Skip to main content

Advertisement

Treatment of HIV-2 infection with ritonavir/lopinavir: results at 60 months. A single-center study of 9 patients

Background

In vitro and in vivo data have suggested that ritonavir/lopinavir is one of the most potent protease inhibitor against HIV-2 infection. Nevertheless, only few clinical reports have been published. So, it seemed to us important to report our clinical experience in 9 patients.

Methods

We searched in our database patients with HIV-2 who have been treated with ritonavir/lopinavir. 9 patients (4 women and 5 men) were identified. Clinical and biological evolution was analyzed.

Results

At the time of initiation of lopinavir, median age was 54 (37-66). Median duration of HIV infection was 41,6 months (6-101). Previous median duration of treatment was 29 months (4-51). No patient was naïve of treatment. The median previous number of regimens received was 2 (1-2). 5/9 patients were naïve of protease inhibitors. Initial median CD4 cells were 150 (68-478). Viral load (VL) was under the limit of detection in 6 cases. Reasons for switching to lopinavir were toxicity or intolerance (n = 2), absence of efficacy on VL (n = 3) or inadequacy of previous treatment (n = 4). In all cases, lopinavir was given in association of 2 NRTIs.

After a median follow-up of 60 months (18-84), no severe side effect was observed. VL under the limits of detection was obtained for all patients except for one patient with a very poor compliance. In this later case, after switching lopinavir to raltegravir, VL remained undetectable. CD4 increased in all cases. The median gain of CD4 from baseline was + 234 (+50 - +472).

Discussion

Because of the very low frequency of the disease in western countries, data on the treatment of HIV-2 infection are uncommon. For these reasons, treatment of HIV-2 patients remains difficult. So, reports on therapeutic options are very important. Even with a modest number of patients, we confirmed the excellent long-term efficiency of lopinavir for the treatment of HIV-2 patients.

Author information

Correspondence to Philippe Genet.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Keywords

  • Protease Inhibitor
  • Viral Load
  • Median Duration
  • Biological Evolution
  • Poor Compliance